Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2007-02-13
2007-02-13
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093300, C435S085000, C435S085000, C435S325000, C435S373000, C435S375000, C435S810000
Reexamination Certificate
active
09162648
ABSTRACT:
This invention provides medicaments and methods for managing cancer using donor cells that are alloactivated in culture. Alloactivated cells are implanted into the bed of a solid tumor and initiate a response by the host against the tumor. Subsequently, alloactivated cells are implanted into the bed of a solid tumor a second time. The two implants work synergistically to confer remarkable benefit to the treated subject, both in terms of management of the cancer and the development of an anti-cancer immune response. The beneficial effects may include regression of the tumor and extended survival. Removal of any residual tumor after the second implant facilitates ongoing resistance to tumor regrowth or metastasis.
REFERENCES:
patent: 5192537 (1993-03-01), Osband
patent: 5308626 (1994-05-01), Landucci et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5602305 (1997-02-01), Pober et al.
patent: 5663481 (1997-09-01), Gallinger et al.
patent: 5837233 (1998-11-01), Granger
patent: 5928639 (1999-07-01), Slavin
patent: 0 379 554 (1996-05-01), None
patent: WO 91/01760 (1991-02-01), None
patent: WO 96/29394 (1996-09-01), None
patent: WO 98/04282 (1998-02-01), None
patent: WO 98/16238 (1998-04-01), None
patent: WO 99/18981 (1999-04-01), None
patent: WO 99/19462 (1999-04-01), None
Jung et al. Clin Exp Immunology, 81(3): 466-474, Sep. 1990.
Haugland RP , Handbook of Fluorescent Probes and Research Chemicals. 5th Ed. Molecular Probes, Inc. pg 172-175, 1992.
Fleshner et al. Cell Transplantation. 1(4): 307-312, 1992.
Klassen, D.J. et al., “Treatment of Locally Unresectable Cancer of the Stomach and Pancreas: A Randomized Comparison of 5-Fluorouracil Alone with Radiation Plus Concurrent and Maintenance 5-Fluorouracil — An Eastern Cooperative Oncology Group Study”J. Clin. Oncol. 3(3):373-378 (1985).
Kruse, C.A. et al., “Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: Chronic therapy for primary brain tumors”J. Neuro-Oncol. 19:161-168 (1994).
Kruse, C.A. et al., “Development of Human Allogeneic CTL in an Artificial Capillary System for Intracavity Treatment of Malignant Glioma”Proc. Am. Assoc. Cancer Res. 36:474 Abstract No. 2822 (1995).
Kruse, C.A. et al., “Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: Allogeneic cytotoxic T lymphocytes prevent tumor take”Proc. Natl. Acad. Sci. USA 87:9577-9581 (1990).
Kruse, C.A. et al., “Immune Therapy of Recurrent Malignant Gliomas: Intracavity Allogeneic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2”FASEB J.10:A 1413 Abstract No. 2387 (1996).
Mallinson et al., “Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial”Br. Med. J. 281:1589-1591 (1980).
Merchant, R.E. et al., “Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes”J. Neuro-Oncol. 8:173-188 (1990).
Miller, T.R. and Fuller, L.M., “Radiation Therapy of Carcinoma of the Pancreas”Am. J. Roentgenol. 80(5):787-792 (1958).
Redd, J.M. et al., “Allogeneic tumor-specific cytotoxic T lymphocytes”Cancer Immunol. Immunother. 34:349-354 (1992).
Rosenberg, S.A. et al., “Gene Transfer into Humans: Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction”New Engl. J. Med. 323:570-578 (1990).
Schirrmacher, V. et al., “Workshop: Active specific immunotherapy with tumor cell vaccines”J. Cancer Res. Clin. Oncol. 121:487-489 (1995).
Vilmann, P. et al., “Endoscopic ultrasonography-guided fine-needle aspiration biopsy of lesions in the upper gastrointestinal tract”Gastrointest. Endosc. 41(3):230-235 (1995).
Wiersema, M.J. et al., “Endosonography-guided real-time fine-needle aspiration biopsy”Gastrointest. Endosc. 40(6):700-707 (1994).
Zarling et al., “Generation of cytotoxic T lymphocytes to autologous human leukaemia cells by sensitisation to pooled allogeneic normal cells”Nature 274:269-271 (1978).
Bernhard, H. et al., “Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial”Br. J. Cancer 71:102-105 (1995).
Chang, K.J. et al., “Endoscopic ultrasound-guided fine-needle aspiration of pancreatic carcinoma”Am. J. Gastroenterol. 89(2):263-266 (1994).
Chang, K.J. et al., “Phase I Clinical Trial of Allogeneic Mixed Lymphocyte Culture (Cytoimplant) Delivered by Endoscopic Ultrasound (EUS)-guided Fine Needle Injection (FNI) in Patients with Advanced Pancreatic Carcinoma”Gastroenterology 112:A546 (1995).
Chang, K.J. et al., “Endoscopic ultrasound-guided fine-needle aspiration”Gastrointest. Endosc. 40(6):694-699 (1994).
Frey, C. et al., “Randomized Study of 5-FU and CCNU in Pancreatic Cancer”Cancer 47:27-31 (1981).
Gastrointestinal Tumor Study Group, “Radiation Therapy Combined with Adriamycin or 5-Fluorouracil for the Treatment of Locally Unresectable Pancreatic Carcinoma”Cancer 56:2563-2568 (1985).
Declaration by Tetsuya Gatanaga Pursuant to 37 CFR § 1.56 Regarding Clinical Trial Conducted under IND-6288 (5 pages).
Appendix A to Declaration by Tetsuya Gatanaga: Curriculum Vitae (15 pages).
Appendix B to Declaration by Tetsuya Gatanaga: Data from Clinical Trial, Protocol AIT-PAN-20 (12 pages).
Hidalgo et al., J. Clin. Oncol. 17:585-92, 1999. “Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer” (Abstract only).
Dugan et al., Pancreas 17:325-33, 1998. “Current concepts in pancreatic cancer: Symposium summary” (Abstract only).
Stephens, Oncol. Nurs. Forum 25:87-93, 1998. “Gemcitabine: A new approach to treating pancreatic cancer” (Abstract only).
Carmichael, Digestion 58:503-7, 1997. “Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine” (Abstract only).
Burris et al., Eur. J. Cancer 33:S18-22, 1997. “Assessing clinical benefit in the tratment of pancreas cancer. Gemcitabine compaed to 5-fluorouracil” (Abstract only).
Rotherberg et al., Ann. Oncol. 7:347-53, 1996. “A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer” (Abstract only).
Carmichael et al., Br. J. Cancer 73:101-5, 1996. “Phase II study of gemcitabine in patients with advanced pancreatic cancer” (Abstract only).
Casper et al., Invest. New Drugs 12:29-34, 1994. “Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas” (Abstract only).
Burris et al., J. Clin. Oncol. 15:2403-13, 1997. “Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial” (Abstract only).
Michael et al., Oncology (Huntingt) 11:1615-22, 1625-7, 1997. “Clinical experience with gemcitabine in pancreatic carcinoma” (Abstract only).
Chen Shin-Lin
Meyer Pharmaceuticals LLC
Schiff J. Michael
LandOfFree
Cancer immunotherapy using allostimulated cells in a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer immunotherapy using allostimulated cells in a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy using allostimulated cells in a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3883573